Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

  • Showing results for a modified search because your search retrieved no results.
1.

Phase 1 trial of Anvirzel in patients with refractory solid tumors.

Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM.

Invest New Drugs. 2006 Sep;24(5):423-7.

PMID:
16763787
2.

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. Epub 2006 Mar 10.

PMID:
16528532
3.

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.

Cancer. 2006 Sep 15;107(6):1383-90.

4.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

5.

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.

Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN.

Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.

PMID:
11761451
6.

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group.

Ann Oncol. 2006 Sep;17(9):1371-8.

7.

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T.

Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. Epub 2007 Jun 27.

PMID:
17594093
8.

Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.

Spunt SL, Freeman BB 3rd, Billups CA, McPherson V, Khan RB, Pratt CB, Stewart CF.

J Clin Oncol. 2007 Jun 1;25(16):2274-80.

9.

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB.

Anticancer Drugs. 2007 Jun;18(5):587-95.

PMID:
17414628
10.

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL.

Invest New Drugs. 2008 Oct;26(5):445-54. doi: 10.1007/s10637-008-9142-3. Epub 2008 Jun 5.

PMID:
18528634
11.

Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.

Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R.

Cancer. 2009 Jan 1;115(1):207-16. doi: 10.1002/cncr.23992.

12.

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.

Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.

Cancer Chemother Pharmacol. 2007 Feb;59(3):285-93. Epub 2006 Jun 20.

PMID:
16786333
13.

Phase I study of everolimus in pediatric patients with refractory solid tumors.

Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL.

J Clin Oncol. 2007 Oct 20;25(30):4806-12.

14.

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.

Children's Oncology Group, Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM.

J Clin Oncol. 2006 Aug 1;24(22):3678-85.

15.

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

Aghajanian C, Burris HA 3rd, Jones S, Spriggs DR, Cohen MB, Peck R, Sabbatini P, Hensley ML, Greco FA, Dupont J, O'Connor OA.

J Clin Oncol. 2007 Mar 20;25(9):1082-8. Epub 2007 Jan 29.

16.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

17.

Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.

Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC; Children's Oncology Group.

J Clin Oncol. 2007 Apr 20;25(12):1505-11. Erratum in: J Clin Oncol. 2008 Jan 1;26(1):165.

18.

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI.

Clin Cancer Res. 2007 Oct 1;13(19):5855-61.

19.

Phase I study of adozelesin (U-73,975) in patients with solid tumors.

Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhart RH.

Anticancer Drugs. 1994 Feb;5(1):10-4.

PMID:
8186423
20.

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.

Cancer Biol Ther. 2006 Jan;5(1):22-7. Epub 2006 Jan 22.

PMID:
16357512
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk